The stimulatory loop formed by GHRH and its receptors can be blocked by GHRH antagonists, which exhibit antitumor functions across various cancer types, by directly inhibiting SV1 signaling or blocking tumor-derived insulin-like growth factor 1 (IGF1) and IGF2. The gene discussed is IGF2; the disease is neoplasm.